Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 666 results for kidney or kidneys or renal

  1. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

    NICE guideline
    Published
    6 July 2016
    View recommendations

    Sections for NG49

  2. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

    Clinical guideline
    Last updated
    18 January 2023
    View recommendations

    Sections for CG103

  3. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

    Technology appraisal guidance
    Published
    25 August 2004
    View recommendations

    Sections for TA82

  4. Further research into the comparative efficacy and safety of different surgical and ablative treatments would be useful.

    guidance details Comes from guidance Laparoscopic cryotherapy for renal cancer Number IPG405 Date issued August 2011 Other

    Research recommendation
    Published
    9 June 2015

  5. Cardiac assessment:- What is the clinical and cost effectiveness of cardiac assessment before transplantation?

    and impact. Source guidance details Comes from guidance Renal replacement therapy and conservative management Number NG107

    Research recommendation
    Published
    18 December 2018

  6. Alpha blockers and ureteroscopy- What is the clinical and cost effectiveness of tamsulosin as an adjunct to ureteroscopy?

    and impact. Source guidance details Comes from guidance Renal and ureteric stones: assessment and management Number NG118

    Research recommendation
    Published
    7 March 2019

  7. Timing of pre-emptive transplant:- What is the most clinical and cost-effective strategy for timing of pre-emptive transplantation?

    and impact. Source guidance details Comes from guidance Renal replacement therapy and conservative management Number NG107

    Research recommendation
    Published
    18 December 2018

  8. Frequency of review:- What is the most clinical and cost-effective frequency of review for people on peritoneal dialysis, haemodiafiltration, haemodialysis or conservative management?

    and impact. Source guidance details Comes from guidance Renal replacement therapy and conservative management Number NG107

    Research recommendation
    Published
    18 December 2018

  9. Metabolic assessment:- What is the clinical and cost effectiveness of full metabolic assessment compared with standard advice alone, in people with recurrent calcium oxalate stones?

    and impact. Source guidance details Comes from guidance Renal and ureteric stones: assessment and management Number NG118

    Research recommendation
    Published
    7 March 2019

  10. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA698

  11. Acute haemodialysis versus acute peritoneal dialysis:- What is the clinical and cost effectiveness of initial haemodialysis versus initial peritoneal dialysis for people who start dialysis in an unplanned way?

    and impact. Source guidance details Comes from guidance Renal replacement therapy and conservative management Number NG107

    Research recommendation
    Published
    18 December 2018

  12. 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people who are having an acute exacerbation of their chronic condition and are unable to exercise, evidence of efficacy is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.   Find out  what standard arrangements mean on the NICE website . For people who are able to exercise, evidence on efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out  what only in research means on the NICE website .

    strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people...

    Research recommendation
    Published
    10 August 2020

  13. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

    Medtech innovation briefing
    Published
    9 September 2015

  14. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    have increased CVD risk derived from age, sex, glycaemia, blood pressure, renal function and lipid levels as identified in...

    Research recommendation
    Published
    9 June 2015

  15. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    guidance details Comes from guidance Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment...

    Research recommendation
    Published
    9 June 2015